Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914438110> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2914438110 endingPage "TPS462" @default.
- W2914438110 startingPage "TPS462" @default.
- W2914438110 abstract "TPS462 Background: Dysregulation of fibroblast growth factor receptor (FGFR) signaling by FGFR genetic alterations is implicated in many cancers, including cholangiocarcinoma (CCA). FGFR2 translocations with fusion partners occur in ≈10% to 20% of intrahepatic CCA tumors. Pemigatinib is a selective oral inhibitor of FGFR-1, 2, 3. Preliminary data from the ongoing phase 2 study show efficacy and tolerable safety in patients (pts) with CCA with FGFR2 translocations. We present the design for a phase 3, open-label, randomized trial investigating pemigatinib monotherapy versus gemcitabine plus cisplatin chemotherapy in the first-line treatment of pts with advanced/metastatic or unresectable CCA with FGFR2 rearrangement. Methods: Eligible pts (target, N = 432) are ≥ 18 years (≥ 20 years for Japanese pts) and have ECOG performance status ≤ 1 and histologically confirmed advanced (locally advanced, metastatic, or recurrent) CCA with a documented FGFR2 rearrangement. Key exclusion criteria include prior systemic therapy, excluding adjuvant/neoadjuvant treatment completed ≥ 6 months before enrollment; current evidence of clinically significant corneal or retinal disorder; history of calcium and phosphate homeostasis disorder or systemic mineral imbalance with ectopic calcification of soft tissues; and known, untreated CNS metastases or history of uncontrolled seizures. Pts are randomized 1:1 and stratified by geographic region and tumor burden into 2 treatment groups: pemigatinib starting dose 13.5 mg once daily continuously on a 3-week cycle; or gemcitabine (1000 mg/m 2 ) and cisplatin (25 mg/m 2 ) administered intravenously on days 1 and 8 of every 3-week cycle for up to 8 cycles until disease progression or unacceptable toxicity. Crossover to pemigatinib may be allowed once progressive disease is confirmed. The primary endpoint is progression-free survival (based on independent central review using RECIST v1.1). Secondary endpoints include overall response rate, overall survival, duration of response, disease control rate, safety and tolerability, and impact on quality of life. Clinical trial information: NCT03656536." @default.
- W2914438110 created "2019-02-21" @default.
- W2914438110 creator A5018257387 @default.
- W2914438110 creator A5031170152 @default.
- W2914438110 creator A5049680516 @default.
- W2914438110 creator A5056650768 @default.
- W2914438110 creator A5057795879 @default.
- W2914438110 creator A5074891676 @default.
- W2914438110 creator A5077826150 @default.
- W2914438110 creator A5079645039 @default.
- W2914438110 creator A5081273660 @default.
- W2914438110 date "2019-02-01" @default.
- W2914438110 modified "2023-10-02" @default.
- W2914438110 title "Trial design for a phase 3 study evaluating pemigatinib (INCB054828) versus gemcitabine plus cisplatin chemotherapy in first-line treatment of patients with cholangiocarcinoma with FGFR2 rearrangement." @default.
- W2914438110 doi "https://doi.org/10.1200/jco.2019.37.4_suppl.tps462" @default.
- W2914438110 hasPublicationYear "2019" @default.
- W2914438110 type Work @default.
- W2914438110 sameAs 2914438110 @default.
- W2914438110 citedByCount "5" @default.
- W2914438110 countsByYear W29144381102019 @default.
- W2914438110 countsByYear W29144381102020 @default.
- W2914438110 countsByYear W29144381102021 @default.
- W2914438110 countsByYear W29144381102023 @default.
- W2914438110 crossrefType "journal-article" @default.
- W2914438110 hasAuthorship W2914438110A5018257387 @default.
- W2914438110 hasAuthorship W2914438110A5031170152 @default.
- W2914438110 hasAuthorship W2914438110A5049680516 @default.
- W2914438110 hasAuthorship W2914438110A5056650768 @default.
- W2914438110 hasAuthorship W2914438110A5057795879 @default.
- W2914438110 hasAuthorship W2914438110A5074891676 @default.
- W2914438110 hasAuthorship W2914438110A5077826150 @default.
- W2914438110 hasAuthorship W2914438110A5079645039 @default.
- W2914438110 hasAuthorship W2914438110A5081273660 @default.
- W2914438110 hasConcept C126322002 @default.
- W2914438110 hasConcept C141071460 @default.
- W2914438110 hasConcept C143998085 @default.
- W2914438110 hasConcept C2776694085 @default.
- W2914438110 hasConcept C2777240266 @default.
- W2914438110 hasConcept C2778239845 @default.
- W2914438110 hasConcept C2778336483 @default.
- W2914438110 hasConcept C2780258809 @default.
- W2914438110 hasConcept C31760486 @default.
- W2914438110 hasConcept C71924100 @default.
- W2914438110 hasConcept C90924648 @default.
- W2914438110 hasConceptScore W2914438110C126322002 @default.
- W2914438110 hasConceptScore W2914438110C141071460 @default.
- W2914438110 hasConceptScore W2914438110C143998085 @default.
- W2914438110 hasConceptScore W2914438110C2776694085 @default.
- W2914438110 hasConceptScore W2914438110C2777240266 @default.
- W2914438110 hasConceptScore W2914438110C2778239845 @default.
- W2914438110 hasConceptScore W2914438110C2778336483 @default.
- W2914438110 hasConceptScore W2914438110C2780258809 @default.
- W2914438110 hasConceptScore W2914438110C31760486 @default.
- W2914438110 hasConceptScore W2914438110C71924100 @default.
- W2914438110 hasConceptScore W2914438110C90924648 @default.
- W2914438110 hasIssue "4_suppl" @default.
- W2914438110 hasLocation W29144381101 @default.
- W2914438110 hasOpenAccess W2914438110 @default.
- W2914438110 hasPrimaryLocation W29144381101 @default.
- W2914438110 hasRelatedWork W2039241971 @default.
- W2914438110 hasRelatedWork W2069948028 @default.
- W2914438110 hasRelatedWork W2100029565 @default.
- W2914438110 hasRelatedWork W2136403887 @default.
- W2914438110 hasRelatedWork W2621339296 @default.
- W2914438110 hasRelatedWork W2977610808 @default.
- W2914438110 hasRelatedWork W3180757786 @default.
- W2914438110 hasRelatedWork W3193404720 @default.
- W2914438110 hasRelatedWork W4250822077 @default.
- W2914438110 hasRelatedWork W2102678840 @default.
- W2914438110 hasVolume "37" @default.
- W2914438110 isParatext "false" @default.
- W2914438110 isRetracted "false" @default.
- W2914438110 magId "2914438110" @default.
- W2914438110 workType "article" @default.